NPR interviews Robert J. Beall, Ph.D., president and CEO of the Cystic Fibrosis Foundation, about the Foundation’s sale of royalty rights to CF treatments and what the expanded resources mean
The CF Foundation and Vertex have had tremendous success in moving the Vertex drugs, VX-809 and VX-661 forward. These drugs have been developed to correct the most common mutation, Delta
The CF Foundation announced a $15 million research initiative with biopharmaceutical company Shire to support the development of a new cystic fibrosis treatment targeting the underlying cause of the disease.
Consider signing up for 2015 Team Run for Roses and particpate in the GO! St. Louis Marathon Events on April 11-12, 2015. Run or Walk in the GO! St. Louis
Sign Up to Receive Rose Foundation Email Updates!
Running 'til CF stands for CURE FOUND!